Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218179 · ClinicalTrials.gov registry record
Assessing the Link Between Smoke Carcinogen Biomarkers and Lung Cancer Risk - 1
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 200
- Enrollment target
NCT00218179: Completed study, sponsored by University of Minnesota.
NCT00218179 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00218179 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
Lung cancer is the leading cause of cancer death in the United States. Currently it remains impossible to predict which smokers will get cancer. Each puff of a cigarette delivers a mixture of over 60 known carcinogens. Biomarkers that quantify carcinogen levels and metabolism are a useful tool and available to use. The purpose of this study is to assess the link between tobacco smoke carcinogen biomarkers and the risk of developing lung cancer.
Interventions
- OTHER Non-intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-12 |
What the finished NCT00218179 record still lists
NCT00218179 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Non-intervention is the first listed.
NCT00218179 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00218179 about?
NCT00218179 is a clinical study titled "Assessing the Link Between Smoke Carcinogen Biomarkers and Lung Cancer Risk - 1". Lung cancer is the leading cause of cancer death in the United States. Currently it remains impossible to predict which smokers will get cancer. Each puff of a cigarette delivers a mixture of over 60 known carcinogens. Biomarkers that quantify carcinogen levels and metabolism are a useful tool and a...
What is the current status of trial NCT00218179?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2005-09. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00218179?
The interventions under investigation include: Non-intervention (OTHER).
Who is sponsoring clinical trial NCT00218179?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia